Technical Analysis for RCUS - Arcus Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | -3.83% | |
| Gapped Up | Strength | -3.83% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -0.47% | |
| Calm After Storm | Range Contraction | -0.47% | |
| Multiple of Ten Bullish | Other | -0.47% | |
| Inside Day | Range Contraction | -0.47% | |
| Gapped Down | Weakness | -0.47% | |
| Calm After Storm | Range Contraction | -1.63% | |
| Multiple of Ten Bullish | Other | -1.63% | |
| Bearish Engulfing | Bearish | -0.27% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 1 hour ago |
| 10 DMA Support | about 2 hours ago |
| 2x Volume Pace | about 2 hours ago |
| 1.5x Volume Pace | about 2 hours ago |
| 3x Volume Pace | about 2 hours ago |
Get a Trading Assistant
- Earnings date: 05/08/2023
Arcus Biosciences, Inc. Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Clinical Development Cancer Treatment Cancer Immunotherapy Monoclonal Antibodies Immunotherapies Adenosine Cd73 Pd 1
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 36.13 |
| 52 Week Low | 15.7 |
| Average Volume | 898,506 |
| 200-Day Moving Average | 22.68 |
| 50-Day Moving Average | 18.52 |
| 20-Day Moving Average | 19.09 |
| 10-Day Moving Average | 19.42 |
| Average True Range | 1.27 |
| RSI (14) | 59.68 |
| ADX | 16.64 |
| +DI | 31.69 |
| -DI | 17.75 |
| Chandelier Exit (Long, 3 ATRs) | 18.69 |
| Chandelier Exit (Short, 3 ATRs) | 20.73 |
| Upper Bollinger Bands | 21.54 |
| Lower Bollinger Band | 16.65 |
| Percent B (%b) | 0.89 |
| BandWidth | 25.59 |
| MACD Line | 0.54 |
| MACD Signal Line | 0.27 |
| MACD Histogram | 0.2649 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 22.38 | ||||
| Resistance 3 (R3) | 22.24 | 21.66 | 22.15 | ||
| Resistance 2 (R2) | 21.66 | 21.31 | 21.72 | 22.07 | |
| Resistance 1 (R1) | 21.33 | 21.09 | 21.50 | 21.47 | 22.00 |
| Pivot Point | 20.75 | 20.75 | 20.83 | 20.81 | 20.75 |
| Support 1 (S1) | 20.42 | 20.40 | 20.59 | 20.56 | 20.02 |
| Support 2 (S2) | 19.84 | 20.18 | 19.90 | 19.95 | |
| Support 3 (S3) | 19.51 | 19.84 | 19.87 | ||
| Support 4 (S4) | 19.65 |
